$12.88
+0.09 (+0.70%)
Open$13.01
Previous Close$12.79
Day High$13.04
Day Low$12.82
52W High$15.35
52W Low$6.62
Volume—
Avg Volume487.6K
Market Cap1.20B
P/E Ratio—
EPS$-1.49
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+389.2% upside
Current
$12.88
$12.88
Target
$63.01
$63.01
$47.40
$63.01 avg
$83.78
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 94.55M | 54.88M | 298.22M |
| Net Income | -132,670,318 | -69,311,711 | -30,982,952 |
| Profit Margin | -140.3% | -133.3% | -10.4% |
| EBITDA | -122,756,718 | -67,695,409 | -39,492,333 |
| Free Cash Flow | — | — | -35,501,473 |
| Rev Growth | +72.3% | +72.3% | -0.7% |
| Debt/Equity | 1.08 | 1.08 | 0.77 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |